Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Non-Current Deferred Tax Liability of $47.5 million for Q1 2026, up 10.73% quarter-over-quarter from $42.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $47.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $47.5 million; the TTM figure through Mar 2026 stood at $47.5 million (changed N/A YoY), while the FY2025 annual figure was $42.9 million, down 57.25% from the prior year.
- Non-Current Deferred Tax Liability advanced to $47.5 million in Q1 2026 per HALO's latest filing, from $42.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $100.4 million in Q4 2024 and bottomed at $3.3 million in Q2 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $32.1 million across 4 years, with a median of $21.3 million in 2022.
- On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 31.24% in 2025 and fell as far as 57.25% in 2025.
- Halozyme Therapeutics' Non-Current Deferred Tax Liability stood at $29.0 million in 2022, then jumped by 246.36% to $100.4 million in 2024, then plunged by 57.25% to $42.9 million in 2025, then increased by 10.73% to $47.5 million in 2026.
- Business Quant data shows HALO's Non-Current Deferred Tax Liability at $47.5 million in Q1 2026, $42.9 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.06 Mn |
| Jun 30, 2026 | 49.06 Mn |
| Mar 31, 2026 | 47.53 Mn |
| Mar 31, 2026 | 47.53 Mn |
| Dec 31, 2025 | 42.92 Mn |
| Dec 31, 2025 | 42.92 Mn |
| Sep 30, 2025 | 8.22 Mn |
| Sep 30, 2025 | 8.22 Mn |
| Dec 31, 2024 | 100.41 Mn |
| Dec 31, 2024 | 100.41 Mn |
| Sep 30, 2024 | 11.95 Mn |
| Sep 30, 2024 | 11.95 Mn |
| Jun 30, 2024 | 13.65 Mn |
| Jun 30, 2024 | 13.65 Mn |
| Sep 30, 2022 | 28.99 Mn |
| Sep 30, 2022 | 28.99 Mn |
| Jun 30, 2022 | 3.29 Mn |
| Jun 30, 2022 | 3.29 Mn |